增强铁质中介辐射敏感性通过协同作用的失硫化诱导
Qiuyu Li1, Zede Wu1,2, Siwen Chen1
1Guangzhou Key Laboratory of Tumor Immunology Research, Cancer Research Institute, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, P.R. China.
ACS nano
|December 27, 2024
概括
这项研究开发了新的纳米铁致死诱导剂,以增强放射治疗. 通过结合葡萄糖氧化酶,研究人员克服了铁灭菌耐药性和诱导的二硫化,改善了治疗结果.
科学领域:
- 生物医学工程 生物医学工程
- 癌症治疗 癌症治疗
- 纳米医学是一种纳米医学.
背景情况:
- 铁质对于放射治疗 (RT) 敏感性至关重要,但耐药性,特别是通过SLC7A11-cystine-GSH-GPX4通路,限制了疗效.
- 开发克服铁灭性耐药性的策略对于改善RT结果至关重要.
研究的目的:
- 开发新的纳米铁致死诱导剂,以提高放射治疗的敏感性,并克服固有的抵抗机制.
- 调查铁和脱硫在增强RT疗效方面的协同效应.
主要方法:
- PEGylated Fe-Bi-SS金属有机框架 (FBSP MOFs) 被合成为含有高Z元素的纳米铁灭诱导剂.
- 葡萄糖氧化酶 (GOx) 被纳入MOFs,以耗尽NADPH并抑制SLC7A11介导的铁灭抵抗.
- 在体外和体内,对铁和脱硫的协同诱导进行了评估.
主要成果:
- FBSP MOFs有效地使RT敏感,但SLC7A11的自我适应性上调导致了抵抗.
- 通过将GOx纳入药物,通过终止囊转化为囊的过程,缓解了铁灭症的抵抗力.
- 协同的铁和脱硫诱导增强了治疗效率,而H2O2通过芬顿反应进一步促进了铁.
结论:
- 溶硫脱是一种新的策略,可以克服铁脱的抗性,并提高放射治疗的疗效.
- 开发的GOx载荷的MOF为铁灭介导的放射敏感化提供了一个有前途的方法.
- 这项研究强调了针对二硫化物压力的潜力,以改善癌症治疗.
相关概念视频
Necrosis
4.3K
Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
4.3K
Electron Transport Chain: Complex I and II
11.3K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
11.3K


